Promise and Peril of Population Genomics for the Development of Genome-First Approaches in Mendelian Cardiovascular Disease

• Published in: Circulation. Genomic and precision medicine Vol. 14; no. 1; p. e002964
• Main Author: Parikh, Victoria N
• Format: Journal Article
• Language: English
• Published: United States 01.02.2021
• Subjects: Cardiomyopathy, Dilated - diagnosis; Cardiomyopathy, Dilated - genetics; Cardiovascular Diseases - diagnosis; Cardiovascular Diseases - genetics; Connectin - genetics; Genetic Variation; Genetics, Population; Genomics; Humans; Risk; cardiovascular disease; population genetics; risk; rare disease; allele
• ISSN: 2574-8300
• DOI: 10.1161/circgen.120.002964

The rich tradition of cardiovascular genomics has placed the field in prime position to extend our knowledge toward a genome-first approach to diagnosis and therapy. Population-scale genomic data has enabled exponential improvements in our ability to adjudicate variant pathogenicity based on allele rarity, and there has been a significant effort to employ these sizeable data in the investigation of rare disease. Certainly, population genomics data has great potential to aid the development of a genome-first approach to Mendelian cardiovascular disease, but its use in the clinical and investigative decision making is limited by the characteristics of the populations studied, and the evolutionary constraints on human Mendelian variation. To truly empower clinicians and patients, the successful implementation of a genome-first approach to rare cardiovascular disease will require the nuanced incorporation of population-based discovery with detailed investigation of rare disease cohorts and prospective variant evaluation.